121 related articles for article (PubMed ID: 7574768)
1. [Clinical effects and immunological analysis of intraabdominal and intrapleural injection of lentinan for malignant ascites and pleural effusion of gastric carcinoma].
Hazama S; Oka M; Yoshino S; Iizuka N; Wadamori K; Yamamoto K; Hirazawa K; Wang F; Ogura Y; Masaki Y
Gan To Kagaku Ryoho; 1995 Sep; 22(11):1595-7. PubMed ID: 7574768
[TBL] [Abstract][Full Text] [Related]
2. [Effect of intrapleural and/or intraperitoneal lentinan therapy in carcinomatous pleuritis and peritonitis].
Yoshino S; Oka M; Hazama S; Suzuki T
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 2):1588-91. PubMed ID: 2389953
[TBL] [Abstract][Full Text] [Related]
3. Immunological analysis and clinical effects of intraabdominal and intrapleural injection of lentinan for malignant ascites and pleural effusion.
Oka M; Yoshino S; Hazama S; Shimoda K; Suzuki T
Biotherapy; 1992; 5(2):107-12. PubMed ID: 1524950
[TBL] [Abstract][Full Text] [Related]
4. A new approach to the treatment of malignant effusion.
Li DJ; Wang YR; Tan XY; Wang HZ; Yao XD; Ba DN
Chin Med J (Engl); 1990 Dec; 103(12):998-1002. PubMed ID: 2127253
[TBL] [Abstract][Full Text] [Related]
5. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
[TBL] [Abstract][Full Text] [Related]
6. Soluble HLA class I molecules in malignant pleural and peritoneal effusions and its possible role on NK and LAK cytotoxicity.
Amirghofran Z; Sheikhi AK; Kumar PV; Saberi Firouzi M
J Cancer Res Clin Oncol; 2002 Aug; 128(8):443-8. PubMed ID: 12200601
[TBL] [Abstract][Full Text] [Related]
7. Without prior stimulation, tumor-associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3.
Strauss G; Gückel B; Wallwiener D; Moldenhauer G
Clin Cancer Res; 1999 Jan; 5(1):171-80. PubMed ID: 9918216
[TBL] [Abstract][Full Text] [Related]
8. [The cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells].
Guo Y; Xing Z
Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):80-2, 127. PubMed ID: 7553955
[TBL] [Abstract][Full Text] [Related]
9. [Effectiveness of treatment with transfer of autologous or allogenic LAK cells combined with rIL-2 in 121 patients with malignant pleural effusion].
Liu X
Zhonghua Zhong Liu Za Zhi; 1993 May; 15(3):205-8. PubMed ID: 8261867
[TBL] [Abstract][Full Text] [Related]
10. [In vitro induction of cytotoxic activity against carcinomatous pleural or peritoneal lymphoid cells cultivated with cytokines, and an immunological phenotypic analysis of the effector cells].
Ebihara T; Koyama S
Gan No Rinsho; 1990 Apr; 36(5):604-10. PubMed ID: 2325266
[TBL] [Abstract][Full Text] [Related]
11. A study of the cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells.
Guo YS; Xing ZL
Chin Med J (Engl); 1994 Dec; 107(12):903-5. PubMed ID: 7882727
[TBL] [Abstract][Full Text] [Related]
12. [Induction by local injections of IL-2 of antitumor effector cells and secondary production of cytokines in malignant pleural effusion].
Sone S; Yanagawa H; Nii A; Ozaki T; Ogura T
Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Aug; 30(8):1434-40. PubMed ID: 1434216
[TBL] [Abstract][Full Text] [Related]
13. [Phase III clinical trial of elemenum emulsion in the management of malignant pleural and peritoneal effusions].
Wang J; Zhang H; Sun Y
Zhonghua Zhong Liu Za Zhi; 1996 Nov; 18(6):464-7. PubMed ID: 9387305
[TBL] [Abstract][Full Text] [Related]
14. Profile of T-cell receptor V beta gene usage of cytotoxic T cells induced by intrapleural administration of a streptococcal preparation, OK432, in malignant effusions.
Miyahara E; Yamaguchi Y; Hihara J; Noma K; Toge T
J Exp Ther Oncol; 1996 Jul; 1(4):242-50. PubMed ID: 9414411
[TBL] [Abstract][Full Text] [Related]
15. Combined immunotherapy with intracavital injection of activated lymphocytes, monocyte-derived dendritic cells and low-dose OK-432 in patients with malignant effusion.
Morisaki T; Matsumoto K; Kuroki H; Kubo M; Baba E; Onishi H; Tasaki A; Nakamura M; Inaba S; Katano M
Anticancer Res; 2003; 23(6a):4459-65. PubMed ID: 14666734
[TBL] [Abstract][Full Text] [Related]
16. [Scanning electron microscopic observation of mouse ascitic carcinoma cells after intraperitoneal administration of lentinan].
Kurokawa T; Tamakuma S
Nihon Gan Chiryo Gakkai Shi; 1990 Dec; 25(12):2822-7. PubMed ID: 2074392
[TBL] [Abstract][Full Text] [Related]
17. [Clinical evaluation of the combination treatment of intrapleural or intraperitoneal administration of lentinan and OK-432 for malignant effusion].
Yoshino S; Yoshida S; Maeda N; Maeda Y; Maeda K; Hazama S; Oka M
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2798-800. PubMed ID: 21224717
[TBL] [Abstract][Full Text] [Related]
18. The characterization of peritoneal and pleural exudate cells from malignant effusions.
Oka M; Yoshino S; Hazama S; Shimoda K; Suzuki T
Surg Today; 1993; 23(6):500-3. PubMed ID: 8102920
[TBL] [Abstract][Full Text] [Related]
19. Generation of lymphokine-activated killer (LAK) cell activity from malignant peritoneal effusions.
Chao TY; Hwang WS; Yeh MY
Proc Natl Sci Counc Repub China B; 1995 Apr; 19(2):92-8. PubMed ID: 7624448
[TBL] [Abstract][Full Text] [Related]
20. [Intrapleural administration of LAK cells combined with rIL2 in the treatment of advanced lung cancer with malignant pleural effusion].
Mao G; Gao Z; Wang Q
Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):83-4, 127. PubMed ID: 7553956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
